VIA
TSHA icon

Virtus Investment Advisers’s Taysha Gene Therapies TSHA Stock Holding History

Virtus Investment Advisers’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Buy
57,303
+10,208
+22% +$60.4K 0.09% 291
2026
Q1 		$211K Buy
47,095
+1,149
+3% +$5.34K 0.06% 335
2025
Q4 		$253K Buy
45,946
+3,008
+7% +$14.6K 0.07% 322
2025
Q3 		$140K Buy
42,938
+7,454
+21% +$21.1K 0.04% 388
2025
Q2 		$82K Sell
35,484
-37,473
-51% -$81.4K 0.03% 415
2025
Q1 		$101K Buy
+72,957
New +$122K 0.03% 417

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus Investment Advisers's TSHA Position: Q2 2026 in Review

Virtus Investment Advisers increased its Taysha Gene Therapies (TSHA) stake by 22% in Q2 2026, buying an estimated $60.4K and bringing the position to 57,303 shares worth $390K. The position accounts for 0.09% of the portfolio, ranked #291.

Virtus Investment Advisers first reported a position in TSHA in Q1 2025 and has held it in 6 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Virtus Investment Advisers held 57,303 shares of Taysha Gene Therapies worth $390K as of Q2 2026.
  • Virtus Investment Advisers bought 10,208 Taysha Gene Therapies shares in Q2 2026, an estimated $60.4K.
  • Taysha Gene Therapies made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #291 holding.
  • Virtus Investment Advisers first reported a position in Taysha Gene Therapies in Q1 2025 and has held it in 6 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.